Skip to main content
RemeGen Co., Ltd. logo

RemeGen Co., Ltd. — Investor Relations & Filings

Ticker · 9995 ISIN · CNE1000048G6 LEI · 300300M9HCX4TFAD4I10 HKEX Manufacturing
Open in API
Filings indexed 1,625 across all filing types
Latest filing 2022-09-19 Regulatory Filings
Country CN China
Listing HKEX 9995

About RemeGen Co., Ltd.

http://www.remegen.com

RemeGen Co., Ltd. is a biopharmaceutical company dedicated to the discovery, development, production, and commercialization of innovative biological drugs. The company focuses on creating first-in-class and best-in-class therapeutics to address significant unmet clinical needs, particularly in the critical therapeutic areas of autoimmune diseases, oncology, and ophthalmology. RemeGen utilizes proprietary technology platforms capable of discovering, screening, and developing new molecules and efficiently optimizing production processes. Its pipeline includes a series of innovative biologics, such as Telitacicept, and features 8 clinical pipelines, over 40 clinical trials, and more than 600 patent applications, demonstrating a strong commitment to R&D and innovation in biopharmaceuticals.

Recent filings

Filing Released Lang Actions
VOLUNTARY ANNOUNCEMENT - PRELIMINARY RESULT OF TELITACICEPT IN THE PHASE III COMFIRMATORY STUDY TO TREAT SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) IN CHINA
Regulatory Filings Classification · 95% confidence The document is a voluntary announcement by RemeGen Co., Ltd. regarding the preliminary results of a Phase III clinical study for a drug (telitacicept) treating systemic lupus erythematosus (SLE). It provides study details, preliminary efficacy data, and background information about the drug and disease. There are no financial statements, regulatory certifications, or detailed financial performance data. The document is an announcement of clinical trial results rather than a financial report or regulatory filing. It is also relatively short (4554 characters) and does not indicate it is an official report or filing with financial or governance content. Therefore, it fits best as a Regulatory Filing (RNS) since it is a general regulatory announcement about clinical trial progress and results, which does not fit other specific categories like earnings release or management report.
2022-09-19 English
Interim Report 2022
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Interim Report 2022' and contains detailed sections such as 'Management Discussion and Analysis', financial results for the first half of 2022, segment revenues, and outlook for the second half of 2022. It includes substantive financial data, business reviews, and operational details for a period shorter than a full fiscal year. The length of the document (15,000 characters) and the presence of detailed financial and operational analysis confirm it is a comprehensive interim financial report rather than a brief announcement or a certification. Therefore, the document fits the definition of an Interim / Quarterly Report (IR). H1 2022
2022-09-14 English
DISCLOSEABLE TRANSACTION - PURCHASE OF WEALTH MANAGEMENT PRODUCTS
Capital/Financing Update Classification · 95% confidence The document is an announcement by RemeGen Co., Ltd. regarding the purchase of wealth management products using idle raised proceeds from an A Share Offering. It details multiple agreements with Qingdao Bank for purchasing these products, including principal amounts, terms, and yields. The document discusses the nature of these transactions as discloseable transactions under the Listing Rules, including percentage ratios and reporting requirements. There is no indication that this is a financial report, earnings release, or management discussion. Instead, it is a regulatory announcement about a capital/financing activity involving the use of raised proceeds for wealth management products. The document is lengthy and detailed, not a brief notice or a report publication announcement. Therefore, the most appropriate classification is Capital/Financing Update (CAP).
2022-09-06 English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 August 2022
Regulatory Filings Classification · 95% confidence The document is a monthly return detailing movements in securities, specifically focusing on authorized and issued share capital, share movements, and confirmations related to securities issued by the company. It is addressed to the Hong Kong Exchanges and Clearing Limited and references compliance with listing rules under Chapter 19B of the Exchange Listing Rules. The content includes detailed tables of share capital and issued shares, confirmations by a director, and notes on share issuance and repurchase. There is no indication of it being an annual or interim financial report, audit report, earnings release, or any other report type. Instead, it is a regulatory filing providing updates on share capital and securities movements as required by the exchange. The document length is 7172 characters, which is substantive but the content is clearly a regulatory compliance update rather than a financial report or announcement of a report. Therefore, the most appropriate classification is Regulatory Filings (RNS).
2022-09-06 English
An announcement has just been published by the issuer in the Chinese section of this website, a corresponding version of which may or may not be published in this section
Report Publication Announcement Classification · 95% confidence The document is extremely short (242 characters) and serves as a notification that an announcement has been published elsewhere on the website. It does not contain financial data, meeting details, or specific corporate actions, but rather acts as a pointer to another document. Per the 'Menu vs Meal' rule, this is a Report Publication Announcement.
2022-09-05 English
Monthly Return of Equity Issuer on Movement in Securities for the month ended 31 August 2022
Regulatory Filings Classification · 95% confidence The document is a monthly return report for an equity issuer and Hong Kong Depositary Receipts listed under Chapter 19B of the Exchange Listing Rules. It details movements in authorised and issued share capital, confirms compliance with listing rules, and is submitted to the Hong Kong Exchanges and Clearing Limited. The content focuses on share capital movements and confirmations related to securities issuance, not on financial performance, management changes, or earnings. It is a regulatory compliance filing related to share capital and securities movements, typical of a Regulatory Filing (RNS) rather than a full financial report or announcement of voting results or capital changes. The document length is moderate (6226 characters) and contains detailed regulatory confirmations, fitting the Regulatory Filings category rather than a brief announcement or a full report like Annual Report or Interim Report.
2022-09-02 English

Browse filings by year

22 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.